Catalyst Dossier · compiled by CeliA 🧫
BioXcel Therapeutics, Inc. (BTAI)
Pharmaceutical Preparations · market cap $37M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
8
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
BioXcel Therapeutics (BTAI) is a small-cap pharmaceutical company with 37 employees and a market cap of approximately $28M, trading near $0.92/share. Its lead asset, BXCL501 (sublingual dexmedetomidine film), is in Phase 3 development for agitation, with additional pipeline work in bipolar I disorder, opioid withdrawal, and an oncology combination (BXCL701 plus pembrolizumab in prostate cancer). The company faces a severe liquidity crisis with only $17.2M in cash, a 4.4-month runway, and $105.5M in net debt.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BXCL501 Sublingual Film | Phase 2 | Bipolar I Disorder |
| BXCL501 | Phase 3 | Agitation,Psychomotor |
| Sublingual film containing dexmedetomidine (BXCL501) | Phase 3 | Agitation |
| BXCL701 plus Pembrolizumab | Phase 2 | Prostate Cancer |
| Dexmedetomidine | Phase 2 | Opioid Withdrawal |
| Sublingual film containing Dexmedetomidine | Phase 2 | Agitation,Psychomotor |
| BXCL701 | Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma |
| BXCL501 (180 micrograms) | Phase 2 | Opioid Use Disorder |
Price & technical context
3-month
-23.9%
6-month
-38.1%
12-month
-77.0%
52-wk range
$0.79–$6.80
vs 50-day MA
-11.1%
vs 200-day MA
-36.6%
Realized vol
97.3%
Max drawdown
-95.9%
Daily closes through 2026-08-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BTAI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.